Fibro-Fatty Component is Important for the Long-Term Clinical Events in Patients Who Have Undergone Primary Percutaneous Coronary Intervention by Kim, Wan Ho et al.
33 Copyright © 2012 The Korean Society of Cardiology
Korean Circulation Journal
Introduction
Virtual histology-intravascular ultrasound (VH-IVUS) has the po-
tential to provide detailed qualitative and quantitative information 
of coronary artery disease and can identify four specific coronary pla-
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que components, such as fibrous (FT), fibro-fatty (FF), dense calcified 
(DC), and necrotic core (NC) regions using tissue mapping.
1)
Necrotic core regions are important in vulnerable plaque
2-4) and 
the number of NC regions is larger in patients with acute coronary 
syndrome (ACS) than patients with stable angina.
5-7) Furthermore, 
NC is associated with positive remodeling.
8)9) However, these findings 
have not always been consistent in previous studies.
10)11)
A controversy exists as to whether NC or FF is associated with slow/ 
no reflow after percutaneous coronary intervention (PCI).
4)5)12-15) We 
previously found that fibro-fatty volume (FFV) is associated with 
slow flow in patients with acute myocardial infarction (AMI) who 
underwent primary PCI.
12) But, other investigators have reported that 
NC is associated with slow flow in patients with ACS who under-
went PCI.
4)5)14)15) Some differences existed between the study popu-
lations in these studies. However, no study has reported which com-
ponent is associated with long-term clinical outcomes.
Therefore, we evaluated which coronary plaque components are 34  Coronary Plaque Components and Long-Term Clinical Events
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associated with long-term clinical outcomes using a post-hoc an-
alysis from our previous study that showed a relationship between 
slow flow and plaque composition in patients with AMI who under-
went primary PCI.
12)
 
Subjects and Methods
Study patients and clinical follow-up
The study subjects consisted of 57 consecutive patients who un-
derwent primary PCI for AMI and a VH-IVUS examination from July 
2006 to July 2007. Exclusion criteria included vessel tortuosity, whi-
ch precluded the VH-IVUS examination, a history of PCI or coronary 
artery bypass surgery, and refusal of patient consent. Patient demo-
graphics and laboratory data, including fasting lipid profiles, serum 
glucose, etc were obtained before primary PCI. Written informed con-
sent was obtained from all patients, and the study was approved by 
the hospital ethics committee of Konyang University Hospital.
The primary endpoint was major adverse cardiac events (MACEs). 
Clinical follow-up was performed for a mean of 27.5±18.3 months, 
and follow-up data were obtained from all patients. MACE were do-
cumented by making phone calls (four patients) and by reviewing 
the hospital records (53 patients). MACE was defined as death, AMI, 
stroke, and revascularization. Death was defined as cardiac death 
due to ACS, intractable heart failure, malignant arrhythmia, and sud-
den cardiac death. AMI was defined based on the criteria of clinical 
presentation, electrocardiogram findings, and cardiac enzyme studi-
es (new ST-segment elevation or depression, development of Q waves 
or left bundle branch block on electrocardiogram, or biochemical evi-
dence of necrosis such as total creatine kinase >twice the normal 
upper limit with an elevated creatine kinase-MB isoenzyme or a 
positive troponin). Stroke was defined as a loss of neurological 
function caused by an ischemic event, and this loss persisted for 
more than 24 hours, left residual signs, or was shown by an imag-
ing study. Revascularization was defined as target lesion revascu-
larization (TLR) or PCI for a native, de novo coronary lesion. TLR was 
defined as ischemia-driven PCI of the target lesion due to resteno-
sis or re-occlusion within the stent or in the adjacent 5 mm of the 
distal or proximal segments.
Primary percutaneous coronary intervention
All patients were taking 200 mg/day aspirin plus 75 mg/day clo-
pidogrel (after a 300 mg of clopidogrel loading dose) and received 
intravenous doses of unfractionated heparin during PCI titrated to 
maintain a therapeutic activated coagulation time.
Percutaneous coronary intervention was performed with a fem-
oral or radial approach using a 6 Fr or 7 Fr guiding catheter and 0.014-
inch standard or extra-support coronary guidewires. Balloon-ex-
pandable stents were successfully implanted in all patients after 
predilation with ballooning. 
Intravascular ultrasound examination and analysis
The IVUS examination methods were described previously.
16) The 
VH-IVUS examination was performed with a dedicated VH-IVUS 
console (Volcano Therapeutics, Rancho Cordova, CA, USA) during the 
primary PCI after an intracoronary administration of 100 to 200 µg 
nitroglycerin. A 20-MHz, 2.9 F monorail, electronic Eagle Eye Gold 
IVUS catheter (Volcano Therapeutics) was advanced into the target 
lesion after wiring (n=36, 63.2%) or small sized (1.5 mm diameter) 
ballooning (n=21, 36.8%) to minimize the effect of ballooning on 
plaque morphology, and an automatic pullback at 0.5 mm/s was 
performed to the aorto-ostial junction. The VH-IVUS image was re-
corded on a DVD-ROM for later offline analysis. VH-IVUS uses a spec-
tral analysis of IVUS radiofrequency data to construct a tissue map.
The grey-scale IVUS images were qualitatively and quantitatively 
analyzed according to the criteria of the American College of Cardio-
logy Clinical Expert Consensus Document on IVUS.
17) Reference seg-
ments were analyzed in a similar manner to the target site. The proxi-
mal and distal reference segments were the most normal-looking 
cross sections ≤10 mm distal and proximal to the lesion. The edges 
of the lesion for determining lesion length were defined as the near-
est point of the most normal-looking cross sections ≤10 mm distal 
and proximal to the lesion. Reference data were the average of the 
proximal and distal reference segments. Plaque rupture was defined 
as an ulcerated ruptured plaque contained in a cavity that commu-
nicated with the lumen and an overlying residual fibrous cap frag-
ment. The ruptured cavity area was measured using manual interro-
gation by tracing the leading edge of the cavity and the presumptive 
border with the lumen in a single image slice with the largest cavity 
size.
12) The volume of the ruptured cavity was measured by multi-
plying 0.05 mm by the sum of all the cavity areas in the image slices 
showing a ruptured cavity. 
Spectral analysis of the intravascular ultrasound 
radiofrequency data
These analyses were conducted on the target lesion of the infarct-
related artery using customized software (IVUSLab; Volcano Thera-
peutics) by either examiner (Bae JH and Kwon TG) who was un-
aware of the patient clinical characteristics. The border was auto-
matically detected at the predefined lesion segment for both the 
lumen and the media-adventitia interface. Then, border detection 
was manually corrected in the lesion again after automatically de-
tecting the border. After confirming border detection, the software 
automatically calculated and presented the results. For each frame, 
histological findings were expressed in colors, as previously described 35 Wan Ho Kim, et al.
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(green for FT, green-yellow for FF, white for DC, and red for NC). Ad-
ditionally, the area (mm
2) and percentage of each plaque tissue com-
ponent was expressed as well as the volumetric analysis (mm
3). 
The predictive accuracy of this method with tissue mapping has 
been validated.
1)
Statistical analysis
All analyses were performed with Statistical Package for the So-
cial Sciences (SPSS) version 18.0 (SPSS Inc., Chicago, IL, USA). Values 
are expressed as mean±SD. We used the Student’s t-test and chi-
square test to compare the groups according to the variables. Rele-
vant baseline clinical and VH-IVUS characteristics showing a sig-
nificant difference (p<0.05) were included in the multivariate an-
alysis. Forward-stepwise Cox regression analysis was performed to 
evaluate the independent factors of long-term clinical outcomes in 
study patients. The Kaplan-Meier method was used to analyze event-
free survival. Statistical significance was inferred at p<0.05.
Results
Study population
The study subjects were divided into two groups based on the me-
dian value of each coronary plaque component; patients with high 
FFV (>13.4 mm
3, n=29; 24 males; mean age, 61.3±15.1 years) and pa-
tients with low FFV (≤13.4 mm
3, n=28; 21 males; mean age, 55.6± 
13.5 years) by the median FFV value. Baseline characteristics are 
summarized in Table 1. No significant differences were observed for 
age, gender, coronary artery disease risk factors, clinical presenta-
tion, medications, lipid profile, or cardiac enzymes. The group with 
a higher FFV had a lower left ventricular ejection fraction (52.7± 
10.4% vs. 59.4±10.3%, p=0.022). When we divided the study pop-
ulation according to median value of the necrotic core volume (NCV), 
FV, or dense calcified volume (DCV), no significant findings were ob-
served in terms of demographics and MACE rate (data not shown).
Table 1. Study subject clinical characteristics
Low FFV
(n=28)
High FFV
(n=29)
p
Male, n (%) 21 (75.0) 24 (82.8) 0.473
Age (years) 055.6±13.5 61.3±15.1 0.139
Hypertension, n (%) 11 (39.3) 11 (37.9) 0.916
Diabetes, n (%) 05 (17.9) 05 (17.2) 0.951
Hyperlipidemia, n (%) 07 (25.9) 10 (34.5) 0.487
Smoking, n (%) 17 (60.7) 14 (48.3) 0.346
Cardiogenic shock, n (%) 1 (3.6) 2 (6.9) 0.574
Old MI, n (%) 1 (3.6) 03 (10.3) 0.317
Peak TnI (ng/mL) 17.6±8.5 16.4±8.70 0.601
hs-CRP (mg/dL) 00.36±0.37 0.45±0.39 0.432
Diagnosis, n (%) 0.449
STEMI 22 (78.6) 25 (86.2)
NSTEMI 06 (21.4) 04 (13.8)
Ejection fraction (%) 059.4±10.3 52.7±10.4 0.022
Uric acid (mg/dL) 5.74±1.7 5.24±1.30 0.358
FBS (mg/dL) 126.9±47.8 146.6±51.00 0.142
TC (mg/dL) 183.3±33.6 171.6±44.50 0.278
TG (mg/dL) 127.3±64.8 149.0±108.9 0.384
HDL-C (mg/dL) 045.1±13.9 43.6±9.70 0.645
LDL-C (mg/dL) 118.3±27.9 114.6±29.60 0.647
Fibrinogen (mg/dL) 03.53±1.22 3.73±1.43 0.622
Creatinine (mg/dL) 00.95±0.20 1.26±0.85 0.064
Use of aspiration catheter, n (%) 04 (14.3) 04 (13.8) 0.957
Use of GP IIb/IIIa inhibitor, n (%) 04 (14.3) 2 (6.9) 0.363
Low FFV ≤13.4 mm
3; high FFV >13.4 mm
3. FFV: fibrofatty volume, TnI: tropo-
nine I, hs-CRP: high sensitivity C-reactive protein, STEMI: ST elevation myo-
cardial infarction, NSTEMI: non-ST elevation myocardial infarction, FBS: 
fasting blood sugar, TC: total cholesterol, TG: triglyceride, HDL-C: high den-
sity lipoprotein-cholesterol, LDL-C: low density lipoprotein-cholesterol, GP 
IIb/IIIa inhibitor: glycoprotein IIb/IIIa inhibitor, MI: myocardial infarction 
Table 2. Long-term clinical outcomes according to fibrofatty volume
MACE
Low FFV
(n=28)
High FFV
(n=29)
p
Death (%) 0 (0.0) 3 (10.7) 0.099
AMI (%) 0 (0.0) 2 (6.9)0 0.157
Stroke (%) 0 (0.0) 0 (0.0)0
PCI (%) 2 (8.3) 6 (21.4) 0.192
de novo lesion (%) 0 (0.0) 3 (10.7) 0.099
TLR (%) 2 (8.3) 3 (10.7) 0.772
Total (%) 2 (8.3) 9 (32.1) 0.036
Mean follow-up duration, 27.5±18.3 months, low FFV ≤13.4 mm
3; high 
FFV >13.4 mm
3. MACE: major adverse cardiac events, FFV: fibrofatty vol-
ume, AMI: acute myocardial infarction, PCI: percutaneous coronary inter-
vention, TLR: target lesion revascularization 
Fig. 1. Kaplan-Meier survival curve. Low FFV ≤13.4 mm3; high FFV >13.4 
mm3. MACE: major adverse cardiac events, FFV: fibrofatty volume, AMI: 
acute myocardial infarction, PCI: percutaneous coronary intervention, TLR: 
target lesion revascularization.
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Clinical outcomes
Major adverse cardiac event rates are listed in Table 2. MACE rates 
tended to be higher in the high FFV group, but the result was not sta-
tistically significant. However, patients with a high FFV had a sig-
nificantly higher incidence (32.1% vs. 8.3%, p=0.036) of total MACE 
(death, AMI, stroke, revascularization) than those in the low FFV gr-
oup. The Kaplan-Meier survival estimates showed worse outcomes 
in the high FFV group than those in the low FFV group (log-rank p= 
0.036) (Fig. 1). No stent thrombosis was noted in either group during 
the follow-up. The univariate Cox regression analysis showed that 
significant predictors for total MACE were FFV and plaque burden. 
The multivariate Cox regression analysis, including all significant 
variables as covariates, revealed that FFV was the only significantly 
independent predictor for MACE (hazard ratio, 6.748; 95% confid-
ence interval, 1.168-38.971, p=0.033) (Table 3). 
When we divided the study population according to the abso-
lute and relative FV, NCV, and DCV, no significant findings were 
observed in terms of demographics or MACE rate.
Coronary angiography findings
The coronary angiography findings are summarized in Table 4. 
No significant differences were observed in terms of lesion loca-
tion, reference diameter, type and size of stent, inflation pressure, 
time of VH-IVUS examination, prevalence of thrombus, or Throm-
bolysis in Myocardial Infarction flow grade. However, multi-vessel 
disease was encountered more often in patients with high FFV than 
those with low FFV (69% vs. 28%, p=0.002). Stent length was sig-
nificantly longer in the high FFV group compared with that in the 
low FFV group (25.07±4.71 mm vs. 21.23±4.19 mm, p=0.002). When 
we compared the angiography findings according to the median 
value of FV, DCV, and NCV, we found no significant differences be-
tween the groups.
Virtual histology-intravascular ultrasound findings
The VH-IVUS findings are summarized in Table 5. IVUS lesion le-
ngth was significantly longer in the high FFV group compared with 
that in the low FFV group (25.71±8.33 mm vs. 15.97±6.02 mm, p< 
Table 3. Hazard ratio for major adverse cardiovascular events
Hazard ratio 95% confidence interval p
Ejection fraction 0.801 0.202-3.171 0.751
Multivessel disease 2.419 0.523-11.192 0.259
Plaque area 1.149 0.233-5.658 0.864
Plaque volume 0.268 00.55-1.304 0.103
Fibrofatty volume 6.748 1.168-38.971 0.033
The variables in this model included age, gender, smoking, hypertension, 
diabetes, dyslipidemia, ejection fraction, multi-vessel disease, plaque area, 
plaque volume, plaque burden, fibrous volume, fibrofatty volume, dense 
calcified volume, and necrotic core volume
Table 4. Coronary angiography findings
Low FFV (n=28) High FFV (n=29) p
Multivessel disease, n (%) 08 (28.6) 20 (69.0) 0.002
LAD/LCX/RCA 20/3/5 12/5/12 0.068
Vessel size (mm)
Proximal reference diameter 03.35±0.43 03.48±0.43 0.280
Distal reference diameter 03.18±0.49 03.32±0.49 0.283
Stent
Cyper/Taxus/Endeavor 18/5/5 12/10/7 0.204
Size (mm) 03.25±0.38 03.43±0.44 0.110
Length (mm) 21.23±4.19 25.07±4.71 0.002
Maximal pressure (atm) 14.62±2.87 14.97±2.71 0.644
Time of VH-IVUS examination, n (%) 0.355
After wiring 16 (57.1) 20 (69.0)
After ballooning 12 (42.9) 09 (31.0)
Thrombus, n (%) 15 (53.6) 22 (75.9) 0.078
TIMI grade ≤1 before PCI, n (%) 13 (46.3) 16 (55.2) 0.509
0 12 (42.9) 12 (41.4)
1 1 (3.6) 04 (13.8)
2 09 (32.1) 08 (27.6)
3 06 (21.4) 05 (17.2)
Low FFV ≤13.4 mm
3; high FFV >13.4 mm
3. FFV: fibrofatty volume, LAD: left anterior descending artery, LCX: left circumflex artery, RCA: right coronary artery, 
VH-IVUS: intravascular ultrasound-virtual histology, TIMI: Thrombolysis in Myocardial Infarction, PCI: percutaneous coronary intervention37 Wan Ho Kim, et al.
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0.05). 
A lesion analysis at the minimal lumen area site revealed that 
patients with high FFV had larger vessel area (17.91±5.37 mm
2 vs. 
12.19±3.89 mm
2, p<0.001), larger lumen area (4.10±1.16 mm
2 vs. 
3.78±1.25 mm
2, p=0.017), larger plaque area (15.90±4.65 mm
2 vs. 
10.61±4.30 mm
2, p<0.05), and a larger fibrous area (7.43±3.00 mm
2 
vs. 4.45±2.73 mm
2, p<0.05) than those in the low FFV group. 
Patients with high FFV had larger vessel volume (380.9±172.9 
mm
3 vs. 197.3±86.9 mm
3, p<0.001), larger plaque volume (314.5± 
141.4 mm
3 vs. 141.6±71.6 mm
3, p<0.05), larger plaque burden (61.7± 
5.1% vs. 57.5±8.1%, p=0.021), larger FV (131.3±69.3 mm
3 vs. 49.9± 
28.4 mm
3, p<0.05), and larger NCV (35.2±29.2 mm
3 vs. 21.1±17.3 
mm
3, p=0.032) over the entire lesion length than those in the low-
er FFV group. 
The VH volumetric data of each plaque constituent were divided 
by the length of the examined vessel segment to compensate for 
the different lesion length in each examined vessel. The FV, FFV, 
plaque volume, and vessel volume after adjustment for the differ-
ent examined vessel segments were larger in the high FFV group 
(4.97±1.67 mm
3/mm vs. 3.11±1.63 mm
3/mm, p<0.001; 1.53±0.99 
mm
3/mm vs. 0.54±0.62 mm
3/mm, p<0.001; 12.14±3.27 mm
3/mm 
vs. 8.77±2.95 mm
3/ mm, p<0.001; 19.62±4.87% vs. 15.03±4.16%, 
p<0.001, respectively). However, no significant difference in the 
NCV and DCV was observed between the groups after adjusting for 
lesion length (1.33±0.98 mm
3/mm vs. 1.20±0.78 mm
3/mm, p= 
Table 5. Virtual histology-intravascular ultrasound (VH-IVUS) findings
Low FFV (n=28) High FFV (n=29) p
IVUS lesion length (mm) 15.97±6.02 25.71±8.33 <0.001
Lesion analysis
    Lumen area (mm
2) 3.78±1.25 04.10±1.16 0.017
    Vessel area (mm
2) 12.19±3.890 17.91±5.37 <0.001
    Plaque area (mm
2) 10.61±4.300 15.90±4.65 <0.001
    Plaque burden (%) 70.57±10.58 79.34±5.17 <0.001
    Fibrous area (mm
2) 4.45±2.73 07.43±3.00 <0.001
    Fibrofatty area (mm
2) 0.72±0.85 02.43±2.09 <0.001
    Dense calcified area (mm
2) 0.66±0.67 00.54±0.44 0.439
    Necrotic core volume (mm
2) 1.61±1.21 01.89±1.34 0.419
Volumetric analysis (mm
3)
    Plaque volume, mm
3 (mm
3/mm) 141.6±71.6 (8.77±2.95) 314.5±141.4 (12.14±3.27) <0.001 (<0.001)
    Vessel volume, mm
3 (mm
3/mm) 197.3±86.9 (15.03±4.16) 380.9±172.9 (19.62±4.87) <0.001 (<0.001)
    Plaque burden (%) 57.5±8.10 61.7±5.1 0.021
    Fibrous volume, mm
3 (mm
3/mm) 49.9±28.4 (3.11±1.63) 131.3±69.3 (4.97±1.67) <0.001 (<0.001)
    Fibrofatty volume, mm
3 (mm
3/mm) 6.9±4.2 (0.54±0.62) 36.4±21.4 (1.53±0.99) <0.001 (<0.001)
    Dense calcified volume, mm
3 (mm
3/mm) 9.9±11.2 (0.56±0.59) 13.9±14.5 (0.53±0.52) 0.245 (0.795)
    Necrotic core volume, mm
3 (mm
3/mm) 21.1±17.3 (1.20±0.78) 35.2±29.2 (1.33±0.98) 0.032 (0.591)
Remodeling index 0.98±0.18 01.04±0.15 0.161
Plaque rupture or ulceration, n (%) 25 (89) 29 (100) 0.078
Reference vessel CSA (mm
2)
    Proximal Ref. CSA 16.86±5.170 21.31±5.25 0.002
    Distal Ref. CSA   12.99±3.890 17.18±330 0.001
Low FFV ≤13.4 mm
3; high FFV >13.4 mm
3. FFV: fibrofatty volume, Ref: reference, CSA: cross sectional area
Fig. 2. Area under the curve. FFV: fibrofatty volume.
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0.591). No significant difference was observed for the remodeling 
index, the prevalence of plaque rupture, or ulceration between the 
two groups. 
Finally, we performed an receiver-operating characteristic curve 
analysis to calculate an FFV cutoff value for future MACE in these 
patients. The absolute FFV optimal cut-off point to predict future 
MACE was 12.3 mm
3. As shown in Fig. 2, this cut-off point had a sen-
sitivity of 90.9% and a specificity of 48.8% (area under the curve, 
0.704, p=0.038, 95% confidence interval, 0.526-0.882) (Fig. 2).
Discussion
The main finding of our study was that high FFV over the entire le-
sion length was an important predictor of long-term clinical out-
come in patients with AMI who underwent primary PCI, although 
it is still unclear whether FFV or NCV is associated with slow/no-re-
flow in previous cross-sectional studies.
4)5)12-15) 
The slow/no reflow phenomenon during PCI is associated with in-
creased in-hospital mortality, post-procedural myocardial infarction, 
and poor mid-term clinical outcomes.
18-20) However, controversies 
exist for the association between plaque components and slow/no 
reflow phenomenon after PCI in patients with ACS.
5)12-15)21) Kawagu-
chi et al.
5) reported that NC volume clearly predicts distal emboli-
zation after stent deployment in patients with an ST-segment eleva-
tion MI, as compared with FT, FF, DC, and total plaque volume. Bae et 
al.
12) reported that patients with slow flow had more FT and FF vol-
umes, but not NC volume, at the time of primary PCI for AMI. Naka-
mura et al.
13) reported that VH-IVUS showed a trend towards a larger 
percentage of FF plaque volume in a no-reflow group than that in 
a normal-reflow group. Hong et al.
15) also reported that NC is associ-
ated with slow flow after PCI in patients with ACS. Thus, no consen-
sus exists regarding plaque composition associated with slow flow.
Several studies have demonstrated that NC is larger in patients 
with ACS than in patients with stable angina.
5-7) Three studies
5-7) 
reported that the amount of NC or the percentage of NC and its ra-
tio to DC are larger in patients with ACS compared to those with 
stable angina. There is also discrepancy with regards to vascular re-
modeling. That is, positive remodeling, which is an adverse prog-
nostic factor, is associated with NC,
8)9) whereas others have report-
ed it is associated with FFV.
10)11) Therefore, it is still unclear whether 
NCV or FFV is associated with ACS, positive remodeling, and slow 
flow in several cross-sectional studies.
2-11) 
Few studies have investigated the impact of coronary plaque 
components on long-term clinical events in patients who under-
went PCI. Therefore, this study was conducted to evaluate the im-
pact of plaque components on long-term clinical events in a ho-
mogenous study population, particularly in patients who under-
went primary PCI. Our study showed that FFV rather than NCV was 
associated with long-term clinical outcome. The reason why FFV, not 
NCV, was associated with total MACE in our study was the greater 
chance for an NCV artifact, particularly by calcium. That is, there was 
a greater chance to be read as NCV behind calcium. The second 
reason was that there was a larger number of already ruptured 
plaque cavities, which precluded true measurement of NCV in the 
lesion. A fresh thrombus is composed of a layered pattern of plate-
let fibrin, erythrocytes, and intact granulocytes, and an old throm-
bus shows in-grown smooth muscle cells with or without deposi-
tion of connective tissue and capillary vessel in-growth, which is 
similar to a fibrous plaque.
22)23)
The current study had some limitations. This study was based on 
a small number of patients, and was a single-center study. Howev-
er, our study was based on consecutive patients with AMI who un-
derwent primary PCI, although we did not reflect the whole spec-
trum of patients with ACS. The other limitation considers thrombi. 
Actually, VH-IVUS cannot identify a thrombus that commonly fol-
lows a plaque rupture. Most lesions (53 of 57, 94.7%) in the cur-
rent study had already ruptured or became ulcerated plaques, whose 
cavity was linked to the lumen. Nasu et al.
24) have shown that th-
rombi are colored as FT and FF by VH-IVUS. Therefore, we analyzed 
the lesions, excluding the plaque cavity to avoid any possible th-
rombus; thus, a larger amount of NCV may have migrated into the 
distal coronary bed before or during primary PCI in the patients with 
AMI. Thus, there was possibility of failing to detect a higher NCV 
and of underestimating NCV. Finally, we arbitrarily divided the study 
population into two groups according to the median value of pla-
que components, because we focused only on the clinical outcomes 
according to coronary plaque components, and there was no cutoff 
value or appropriate value for absolute plaque components until now.
Conclusion
Our results suggest that plaque components, particularly FFV, but 
not NCV, are important in the long-term clinical outcomes of pa-
tients who underwent primary PCI, although further studies are ne-
eded to evaluate the relationship between coronary plaque com-
ponents and long-term clinical outcomes. A VH-IVUS analysis for 
plaque components over the entire lesion may be useful to predict 
the risk of long-term clinical outcomes in patients with AMI who 
underwent primary PCI. Lesions with high FFV should trigger more 
aggressive secondary prevention in patients with AMI who under-
went primary PCI.
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